Robert Dreicer

4 ta ish

University of Virginia

1. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

   Karen A. Autio, Robert Dreicer, Justine Anderson +13

   MaqolaOAOchiq kirish20183 iqtibos

   ABIABI:AkademIndex/2026.other.051877

2. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

   Philip W. Kantoff, Celestia S. Higano, Neal D. Shore +10

   MaqolaOAOchiq kirish20103 iqtibos

   ABIABI:AkademIndex/2026.other.082764

3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

   Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles +28

   MaqolaOAOchiq kirish20163 iqtibos

   ABIABI:AkademIndex/2026.other.097028

4. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer

   Pedro C. Barata, Matthew M. Cooney, Prateek Mendiratta +3

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.003160